查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球糖清蛋白檢測市場：按應用（初發糖尿病,1型/2型糖尿病）,最終用戶（醫院/糖尿病治療中心,診斷實驗室）和地區（北美,歐洲,亞太,拉美,中東/非洲）預測到2028
市場調查報告書
商品編碼
1309762

全球糖清蛋白檢測市場：按應用（初發糖尿病,1型/2型糖尿病）,最終用戶（醫院/糖尿病治療中心,診斷實驗室）和地區（北美,歐洲,亞太,拉美,中東/非洲）預測到2028

Glycated Albumin Assay Market by Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User (Hospitals & Diabetic Care Center, Diagnostic Laboratory) & Region (North America, Europe, APAC, Latin America, & MENA) - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 124 Pages | 訂單完成後即時交付

價格
簡介目錄

全球糖化白蛋白檢測市場規模預計將從 2023 年的 2 億美元增長到 2028 年的 3 億美元，預測期內復合年增長率為 8.9%。

市場增長是由 65 歲以上糖尿病患者數量不斷增加以及政府對疾病診斷的承諾等因素推動的。 另一方面，不利的還款場景等挑戰是市場增長的主要製約因素。

“在預測期內，邊緣型糖尿病將按應用增長最快”

通過按應用分析糖化白蛋白檢測市場，邊緣性糖尿病將在 2022 年擁有最高的市場增長率。 新興國家對預防糖尿病等生活方式疾病的興趣日益濃厚,診斷實驗室的增加以及醫療基礎設施的改善是促進該細分市場增長的主要因素。

“診斷實驗室領域將在預測期內實現最終用戶的最高增長率”

根據最終用戶的糖化白蛋白檢測市場，診斷實驗室細分市場將在 2022 年實現最高增長率。 診斷實驗室為醫療保健提供者和患者提供了一種經濟高效且方便的測試選擇。 通過將糖化白蛋白檢測外包給診斷實驗室，醫療保健提供者可以避免對內部檢測設施和相關成本的需求。 此外，患者可以前往診斷實驗室進行糖化白蛋白測定，而無需住院或專科醫院就診。 由於其成本效益和便利性，診斷實驗室是一個有吸引力的選擇，導致需求增加和該領域的增長。

“亞太地區：糖清蛋白檢測市場增長最快的地區”

按地區查看全球糖化白蛋白檢測市場，預計亞太地區在預測期內的複合年增長率最高。 由於糖尿病意識計劃的增加和政府醫療保健政策的積極影響，該地區的糖化白蛋白測定市場正在擴大。

內容

第一章簡介

第 2 章研究方法

第 3 章執行摘要

第 4 章重要考慮因素

第五章市場概述

  • 簡介
  • 市場動態
    • 驅動程序
    • 制約因素
    • 機會
    • 任務
  • 價格分析
  • 專利分析
  • 價值鏈分析
  • 供應鏈分析
  • 生態系統分析
  • 波特五力分析
  • 監管狀況
  • 貿易分析
  • 技術分析
  • 重大會議和活動
  • 杵分析
  • 影響客戶業務的趨勢/干擾
  • 主要利益相關者和採購標準
  • 案例研究分析

第 6 章糖基化白蛋白檢測市場：按應用劃分

  • 簡介
  • 2 型糖尿病
  • 邊緣性糖尿病
  • 1 型糖尿病

第 7 章糖清蛋白檢測市場：按最終用戶劃分

  • 簡介
  • 醫院和糖尿病治療中心
  • 診斷實驗室
  • 其他最終用戶

第 8 章糖清蛋白檢測市場：按地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 亞太地區其他地區
  • 拉丁美洲
  • 中東和非洲

第 9 章競爭格局

  • 概述
  • 主要公司的收入份額分析
  • 市場份額分析
  • 糖化白蛋白檢測市場：公司評估矩陣
  • 糖化白蛋白檢測市場：初創公司/中小企業公司評估矩陣（2022 年）
  • 競爭基準測試

第 10 章公司簡介

  • 主要公司
    • ASAHI KASEI CORPORATION
    • BEIJING STRONG BIOTECHNOLOGIES, INC.
    • DIAZYME LABORATORIES, INC.
    • DXGEN CORP.
    • WELDON BIOTECH, INC.
    • HZYMES BIOTECH

第11章 附錄

簡介目錄
Product Code: MD 8715

The global glycated albumin assay market is projected to reach USD 0.3 billion by 2028 from USD 0.2 billion in 2023, at a CAGR of 8.9% during the forecast period. Market growth is driven by factors such as the increased number of diabetic patients above the age of 65 years and government initiatives for disease diagnosis. On the other hand, challenges associated with the glycated albumin assay market, like unfavorable reimbursement scenarios, are the major factors restricting market growth.

"The prediabetic segment accounted for the highest growth rate in the glycated albumin assay market, by application, during the forecast period"

The glycated albumin assay market is segmented into prediabetes, type 1 diabetes, and type 2 diabetes. In 2022, the prediabetes segment accounted for the highest glycated albumin assay market growth rate. The increasing focus on the prevention of lifestyle diseases like diabetes, growth in the number of diagnostic laboratories, and improving healthcare infrastructure in emerging countries are major factors contributing to this segment's growth.

"The diagnostic laboratories segment accounted for the highest growth in the glycated albumin assay market, by end-user, during the forecast period"

The glycated albumin assay market is segmented into hospitals and diabetes care centers, diagnostic laboratories, and other end-user based on end users. In 2022, the diagnostic laboratories segment accounted for the highest glycated albumin assay market growth rate. Diagnostics laboratories often offer cost-effective and convenient testing options for healthcare providers and patients. By outsourcing glycated albumin testing to diagnostics laboratories, healthcare providers can avoid the need for in-house testing facilities and associated costs. Additionally, patients can visit diagnostics laboratories for their glycated albumin assays without the need for hospitalization or specialized clinic visits. The cost-effectiveness and convenience of diagnostics laboratories make them an attractive option, leading to increased demand and segment growth.

"Asia Pacific: The fastest-growing region in glycated albumin assay market"

The North American, European, Asia Pacific, Latin American, Middle Eastern, and African regions make up the major segments of the worldwide glycated albumin assay market. The highest CAGR is anticipated to be recorded over the forecast period in the Asia Pacific region. The glycated albumin assay market in this region is expanding as a result of an increase in diabetes awareness programmes and favourable government healthcare policies.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6% , and the Middle East & Africa - 4%

List of Companies Profiled in the Report:

  • Asahi Kasei Corporation (Japan)
  • Beijing Strong Biotechnologies, Inc. (China)
  • Diazyme Laboratories, Inc. (US)
  • DxGen Corp. (South Korea)
  • Weldon Biotech, Inc.(India)
  • Hzymes Biotech (China)

Research Coverage:

This report provides a detailed picture of the global glycated albumin assay market. It aims at estimating the size and future growth potential of the market across different segments, such as application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profile and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall glycated albumin assay market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKET SEGMENTATION
    • 1.3.2 GEOGRAPHICAL SCOPE
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 1 GLYCATED ALBUMIN ASSAY MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.3.1.2 Approach 2: Primary interviews
      • 2.3.1.3 Growth forecast
      • 2.3.1.4 Glycated Albumin Assay Market: CAGR Projections
    • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 6 GLYCATED ALBUMIN ASSAY MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION METHODOLOGY
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE ANALYSIS
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 STUDY LIMITATIONS
  • 2.8 GROWTH RATE ASSUMPTIONS
  • 2.9 RISK ASSESSMENT
    • 2.9.1 GLYCATED ALBUMIN ASSAY MARKET: RISK ASSESSMENT ANALYSIS
  • 2.10 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 8 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 9 GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 10 GLYCATED ALBUMIN ASSAY MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 GLYCATED ALBUMIN ASSAY MARKET OVERVIEW
    • FIGURE 11 INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET
  • 4.2 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2023 VS. 2028
    • FIGURE 12 TYPE 2 DIABETES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.3 GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2023 VS. 2028
    • FIGURE 13 HOSPITALS AND DIABETIC CARE CENTERS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.4 GLYCATED ALBUMIN ASSAY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
    • FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 15 GLYCATED ALBUMIN ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of diabetes
    • FIGURE 16 PREVALENCE OF DIABETES IN ADULTS (20-79 YEARS), BY REGION, 2021 VS. 2045 (USD MILLION)
    • TABLE 1 TOTAL HEALTH EXPENDITURE (USD) FOR DIABETES (20-79 YEARS), BY COUNTRY (2021)
      • 5.2.1.2 Growing focus on early detection of diabetes
      • 5.2.1.3 Increase in age-associated diabetic ailments
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable reimbursement scenario
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising investments in life sciences research
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Stringent regulatory requirements for diagnostic products
      • 5.2.4.2 Presence of alternative tests
  • 5.3 PRICING ANALYSIS
    • TABLE 2 AVERAGE SELLING PRICE OF GLYCATED ALBUMIN ASSAY PRODUCTS
  • 5.4 PATENT ANALYSIS
    • FIGURE 17 PATENT ANALYSIS FOR GLYCATED ALBUMIN ASSAYS (JANUARY 2013-DECEMBER 2022)
    • 5.4.1 GLYCATED ALBUMIN ASSAY MARKET: LIST OF MAJOR PATENTS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 18 GLYCATED ALBUMIN ASSAY MARKET: MAJOR VALUE IS ADDED DURING MANUFACTURING & ASSEMBLY PHASES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 19 GLYCATED ALBUMIN ASSAY MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    • FIGURE 20 GLYCATED ALBUMIN ASSAY MARKET: ECOSYSTEM MAP
    • 5.7.1 GLYCATED ALBUMIN ASSAY MARKET: ECOSYSTEM ROLE
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 3 GLYCATED ALBUMIN ASSAY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 REGULATORY LANDSCAPE
    • TABLE 4 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 7 MIDDLE EAST: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.9.1 NORTH AMERICA
      • 5.9.1.1 US
      • 5.9.1.2 Canada
    • 5.9.2 EUROPE
    • TABLE 8 EUROPE: CLASSIFICATION OF DEVICES
    • 5.9.3 ASIA PACIFIC
      • 5.9.3.1 China
      • 5.9.3.2 Japan
      • 5.9.3.3 India
    • 5.9.4 LATIN AMERICA
      • 5.9.4.1 Brazil
      • 5.9.4.2 Mexico
    • 5.9.5 MIDDLE EAST
    • 5.9.6 AFRICA
  • 5.10 TRADE ANALYSIS
    • 5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
      • 5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
      • 5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
  • 5.11 TECHNOLOGY ANALYSIS
  • 5.12 KEY CONFERENCES AND EVENTS
    • TABLE 9 DETAILED LIST OF CONFERENCES AND EVENTS (2022-2023)
  • 5.13 PESTLE ANALYSIS
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 21 GLYCATED ALBUMIN ASSAY MARKET: REVENUE SHIFT MAPPING
  • 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR GLYCATED ALBUMIN ASSAYS
    • TABLE 10 GLYCATED ALBUMIN ASSAY MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
    • 5.15.2 BUYING CRITERIA
    • FIGURE 23 GLYCATED ALBUMIN ASSAY MARKET: KEY BUYING CRITERIA
    • TABLE 11 KEY BUYING CRITERIA FOR GLYCATED ALBUMIN ASSAYS, BY END USER
  • 5.16 CASE STUDY ANALYSIS
    • FIGURE 24 CASE STUDY ANALYSIS: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA

6 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION

  • 6.1 INTRODUCTION
    • TABLE 12 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 6.2 TYPE 2 DIABETES
    • 6.2.1 DIETARY AND LIFESTYLE CHANGES TO CONTRIBUTE TO MARKET GROWTH
    • TABLE 13 GLYCATED ALBUMIN ASSAY MARKET FOR TYPE 2 DIABETES, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 PREDIABETES
    • 6.3.1 INSULIN RESISTANCE AND RISING CASES OF PREDIABETES TO DRIVE MARKET
    • TABLE 14 GLYCATED ALBUMIN ASSAY MARKET FOR PREDIABETES, BY REGION, 2021-2028 (USD MILLION)
  • 6.4 TYPE 1 DIABETES
    • 6.4.1 INCREASING INCIDENCE AMONG CHILDREN AND ADOLESCENTS TO SUPPORT MARKET GROWTH
    • TABLE 15 INCIDENCE OF TYPE 1 DIABETES IN CHILDREN AND ADOLESCENTS AGED 0 TO 19, BY REGION, 2021 (THOUSANDS)
    • TABLE 16 GLYCATED ALBUMIN ASSAY MARKET FOR TYPE 1 DIABETES, BY REGION, 2021-2028 (USD MILLION)

7 GLYCATED ALBUMIN ASSAY MARKET, BY END USER

  • 7.1 INTRODUCTION
    • TABLE 17 GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 7.2 HOSPITALS AND DIABETES CARE CENTERS
    • 7.2.1 ABILITY TO OFFER RAPID RESULTS IN ACCESSIBLE SETTING TO DRIVE MARKET
    • TABLE 18 GLYCATED ALBUMIN ASSAY MARKET FOR HOSPITALS AND DIABETES CARE CENTERS, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 DIAGNOSTIC LABORATORIES
    • 7.3.1 RISING OUTSOURCING OF RESEARCH ACTIVITIES FOR COST REDUCTION TO DRIVE MARKET
    • TABLE 19 GLYCATED ALBUMIN ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
  • 7.4 OTHER END USERS
    • TABLE 20 GLYCATED ALBUMIN ASSAY MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

8 GLYCATED ALBUMIN ASSAY MARKET, BY REGION

  • 8.1 INTRODUCTION
    • TABLE 21 GLYCATED ALBUMIN ASSAY MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 8.2 NORTH AMERICA
    • FIGURE 25 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET SNAPSHOT
    • TABLE 22 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 23 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 24 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.2.1 US
      • 8.2.1.1 High healthcare expenditure for diabetes treatment & diagnosis to drive market
    • TABLE 25 US: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 26 US: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.2.2 CANADA
      • 8.2.2.1 Rising awareness of early diabetes detection to support market growth
    • TABLE 27 INCIDENCE OF DIABETES IN CANADA, 2019 VS. 2029
    • TABLE 28 CANADA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 29 CANADA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.2.3 NORTH AMERICA: RECESSION IMPACT
  • 8.3 EUROPE
    • TABLE 30 PREVALENCE OF DIABETES IN EUROPE, 2021 VS. 2045
    • TABLE 31 EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 32 EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 33 EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.3.1 GERMANY
      • 8.3.1.1 Provision of healthcare coverage for technologically advanced assays to drive market
    • TABLE 34 GERMANY: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 35 GERMANY: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.3.2 UK
      • 8.3.2.1 Rising geriatric population and diabetes-associated ailments to drive market
    • TABLE 36 UK: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 37 UK: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.3.3 FRANCE
      • 8.3.3.1 Increasing R&D expenditure for product commercialization to drive market
    • TABLE 38 FRANCE: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 39 FRANCE: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.3.4 ITALY
      • 8.3.4.1 Improvements in healthcare infrastructure to support market growth
    • TABLE 40 ITALY: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 41 ITALY: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.3.5 SPAIN
      • 8.3.5.1 Rising incidence of diabetes among senior women to support market growth
    • TABLE 42 SPAIN: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 43 SPAIN: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.3.6 REST OF EUROPE
    • TABLE 44 REST OF EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 45 REST OF EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.3.7 EUROPE: RECESSION IMPACT
  • 8.4 ASIA PACIFIC
    • FIGURE 26 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET SNAPSHOT
    • TABLE 46 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 48 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.4.1 CHINA
      • 8.4.1.1 Improving healthcare infrastructure to propel market
    • TABLE 49 CHINA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 50 CHINA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.4.2 JAPAN
      • 8.4.2.1 Universal healthcare reimbursement policy to support market growth
    • TABLE 51 JAPAN: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 52 JAPAN: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.4.3 INDIA
      • 8.4.3.1 implementation of favorable government initiatives to drive market
    • TABLE 53 INDIA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 54 INDIA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.4.4 REST OF ASIA PACIFIC
    • TABLE 55 REST OF ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 56 REST OF ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.4.5 ASIA PACIFIC: RECESSION IMPACT
  • 8.5 LATIN AMERICA
    • 8.5.1 RISING GOVERNMENT-FUNDED PROGRAMS FOR ACCURATE AND EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
    • TABLE 57 LATIN AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 58 LATIN AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.5.2 LATIN AMERICA: RECESSION IMPACT
  • 8.6 MIDDLE EAST & AFRICA
    • 8.6.1 EXPANSION OF KEY MARKET PLAYERS TO SUPPORT MARKET GROWTH
    • TABLE 59 MIDDLE EAST & AFRICA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 60 MIDDLE EAST & AFRICA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS
    • FIGURE 27 GLYCATED ALBUMIN ASSAY MARKET: REVENUE SHARE ANALYSIS
  • 9.3 MARKET SHARE ANALYSIS
    • 9.3.1 GLYCATED ALBUMIN ASSAY MARKET
    • FIGURE 28 GLYCATED ALBUMIN ASSAY MARKET SHARE, BY KEY PLAYER (2022)
    • TABLE 61 GLYCATED ALBUMIN ASSAY MARKET: INTENSITY OF COMPETITIVE RIVALRY
  • 9.4 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX
    • 9.4.1 STARS
    • 9.4.2 EMERGING LEADERS
    • 9.4.3 PERVASIVE PLAYERS
    • 9.4.4 PARTICIPANTS
    • FIGURE 29 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX (2022)
  • 9.5 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
    • 9.5.1 PROGRESSIVE COMPANIES
    • 9.5.2 STARTING BLOCKS
    • 9.5.3 RESPONSIVE COMPANIES
    • 9.5.4 DYNAMIC COMPANIES
    • FIGURE 30 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
  • 9.6 COMPETITIVE BENCHMARKING
    • 9.6.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
    • FIGURE 31 GLYCATED ALBUMIN ASSAY MARKET: PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
    • TABLE 62 GLYCATED ALBUMIN ASSAY MARKET: COMPETITIVE EVALUATION OF KEY PLAYERS
    • TABLE 63 GLYCATED ALBUMIN ASSAY MARKET: COMPANY PRODUCT FOOTPRINT
    • TABLE 64 GLYCATED ALBUMIN ASSAY MARKET: COMPANY REGIONAL FOOTPRINT

10 COMPANY PROFILES

  • (Business overview, Products offered, Recent Developments, MNM view)**
  • 10.1 KEY PLAYERS
    • 10.1.1 ASAHI KASEI CORPORATION
    • TABLE 65 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
    • FIGURE 32 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022)
    • 10.1.2 BEIJING STRONG BIOTECHNOLOGIES, INC.
    • TABLE 66 BEIJING STRONG BIOTECHNOLOGIES, INC.: BUSINESS OVERVIEW
    • FIGURE 33 BEIJING STRONG BIOTECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
    • 10.1.3 DIAZYME LABORATORIES, INC.
    • TABLE 67 DIAZYME LABORATORIES, INC.: COMPANY OVERVIEW
    • 10.1.4 DXGEN CORP.
    • TABLE 68 DXGEN CORP: COMPANY OVERVIEW
    • 10.1.5 WELDON BIOTECH, INC.
    • TABLE 69 WELDON BIOTECH, INC.: COMPANY OVERVIEW
    • 10.1.6 HZYMES BIOTECH
    • TABLE 70 HZYMES BIOTECH: COMPANY OVERVIEW
  • *Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 CUSTOMIZATION OPTIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS